Related Experiment Video
Updated: May 8, 2026
Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates
Published on: January 30, 2014
SMOC2 promotes microglia activity and neuroinflammation in Alzheimer's disease
1Department of Geriatrics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Background:
Alzheimer's disease (AD), the leading cause of dementia, is characterized by cognitive decline and the accumulation of amyloid-β (Aβ). It affects millions, with numbers expected to double by 2050. SMOC2, implicated in inflammation and fibrosis, may play a role in AD pathogenesis, particularly in microglial cell function, offering a potential therapeutic target.
Objective:
Alzheimer's disease (AD) leads to neurodegeneration, affecting cognition, language, and personality, underscoring the urgency for effective treatments. Our study investigates the role of secreted modular calcium-binding protein 2 (SMOC2) in microglial cells and its impact on AD pathology.
Methods:
We introduced SMOC2 overexpression and interference vectors into microglial cells treated with Aβ. Activity and phagocytosis were assessed using CCK8 and flow cytometry. SMOC2 mRNA levels were quantified by qPCR, and protein levels of SMOC2, TGF-β1, p-NF-κB/NF-κB were analyzed by western blot. Aβ content was determined by ELISA, and immunofluorescence detected TNF-α, IL-1β, CD163, and CD206.
Results:
Aβ treatment inhibited microglial activity and phagocytosis, but SMOC2 disruption enhanced these functions (p < 0.05). SMOC2 overexpression increased its expression and Aβ levels, while interference reduced them (p < 0.001). SMOC2 overexpression also decreased TGF-β1, CD163, and CD206, and increased p-NF-κB/NF-κB, TNF-α, and IL-1β (p < 0.05).
Conclusions:
SMOC2 plays a crucial role in microglial cell activity, phagocytosis, and polarization, potentially through the TGF-β1/NF-κB pathway, offering insights into AD pathogenesis.
Insights
Secreted modular calcium-binding protein 2 (SMOC2) influences Alzheimer's disease (AD) pathology by modulating microglial function. Targeting SMOC2 may offer a novel therapeutic strategy for AD by enhancing microglial phagocytosis and reducing amyloid-beta accumulation.
Area of Science:
- Neuroscience
- Immunology
- Cell Biology
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and amyloid-beta (Aβ) accumulation.
- Microglial cells play a critical role in AD pathogenesis, and their function is increasingly recognized as a therapeutic target.
- Secreted modular calcium-binding protein 2 (SMOC2) has been implicated in inflammatory and fibrotic processes, suggesting a potential role in AD.
Purpose of the Study:
- To investigate the role of SMOC2 in microglial cells within the context of Alzheimer's disease pathology.
- To determine the impact of SMOC2 modulation on microglial activity, phagocytosis, and inflammatory responses.
Main Methods:
- Overexpression and interference vectors were used to manipulate SMOC2 levels in Aβ-treated microglial cells.
- Cell activity and phagocytosis were quantified using CCK8 assays and flow cytometry.
- Gene and protein expression levels of SMOC2, inflammatory markers (TNF-α, IL-1β), and microglial polarization markers (CD163, CD206) were analyzed using qPCR, western blot, ELISA, and immunofluorescence.
Main Results:
- Aβ treatment impaired microglial activity and phagocytosis, while SMOC2 interference significantly enhanced these functions.
- SMOC2 overexpression increased Aβ levels and promoted pro-inflammatory responses (increased TNF-α, IL-1β, p-NF-κB/NF-κB), while decreasing anti-inflammatory markers (TGF-β1, CD163, CD206).
- Conversely, SMOC2 interference reduced Aβ levels and modulated inflammatory and polarization markers, suggesting a protective role.
Conclusions:
- SMOC2 significantly influences microglial cell activity, phagocytosis, and polarization in the context of AD.
- The findings suggest that SMOC2 may exert its effects through the TGF-β1/NF-κB signaling pathway.
- Modulating SMOC2 presents a potential therapeutic avenue for Alzheimer's disease by targeting microglial dysfunction.
Related Concept Videos
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
01:29Alzheimer Disease l: Introduction
01:23Alzheimer Disease ll: Pathophysiology